Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Symptoms or adverse events experienced by patients with multiple sclerosis (MS) can affect their health-related quality of life (QOL) and treatment satisfaction, and can be caused by either the disease itself or the disease-modifying therapy (DMT). The EPOC study assessed the effects of switching from an injectable disease-modifying therapy (glatiramer acetate or one of three interferon beta drugs) to once-daily, oral fingolimod 0.5 mg in patients with relapsing MS.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi